Targeting the PI3K signaling pathway in cancer
KK Wong, JA Engelman, LC Cantley - Current opinion in genetics & …, 2010 - Elsevier
KK Wong, JA Engelman, LC Cantley
Current opinion in genetics & development, 2010•ElsevierThe phosphoinositide 3-kinase (PI3K) pathway is activated in a variety of different human
cancers, and inhibitors of this pathway are under active development as anti-cancer
therapeutics. In this review, we discuss the data supporting the use of PI3K pathway
inhibitors in genetically and clinically defined cancers. This review focuses on their efficacy
as single agents and in combination with other targeted therapies, specifically those
targeting the MEK–ERK signaling pathway.
cancers, and inhibitors of this pathway are under active development as anti-cancer
therapeutics. In this review, we discuss the data supporting the use of PI3K pathway
inhibitors in genetically and clinically defined cancers. This review focuses on their efficacy
as single agents and in combination with other targeted therapies, specifically those
targeting the MEK–ERK signaling pathway.
The phosphoinositide 3-kinase (PI3K) pathway is activated in a variety of different human cancers, and inhibitors of this pathway are under active development as anti-cancer therapeutics. In this review, we discuss the data supporting the use of PI3K pathway inhibitors in genetically and clinically defined cancers. This review focuses on their efficacy as single agents and in combination with other targeted therapies, specifically those targeting the MEK–ERK signaling pathway.
Elsevier